• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aerie Pharmaceuticals

Aerie wins FDA nod for second glaucoma drug

March 14, 2019 By Sarah Faulkner

Aerie Pharmaceuticals - updated logo

Aerie Pharmaceuticals (NSDQ:AERI) said this week that the FDA approved the company’s once-daily eye drop Rocklatan for the treatment of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension. The Durham, N.C.-based company’s product is a fixed-dose combination of latanoprost and netarsudil – the active ingredient in Aerie’s first drug, Rhopressa. After winning an […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Aerie Pharmaceuticals

Aerie expands drug-delivery tech deal with DSM Biomedical

August 1, 2018 By Sarah Faulkner

Aerie Pharmaceuticals - updated

Aerie Pharmaceuticals (NSDQ:AERI) said today that it expanded its drug-delivery R&D deal with DSM Biomedical. The two companies first joined forces in July last year to evaluate the sustained delivery of certain Aerie drugs using DSM’s polymer technology. Initially, the group was focused on developing drug-delivery tech for people with wet age-related macular degeneration and diabetic […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, dsmbiomedical

Aerie seeks FDA nod for Roclatan once-daily eye drop

May 15, 2018 By Sarah Faulkner

Aerie Pharmaceuticals - updated

Aerie Pharmaceuticals (NSDQ:AERI) said today that it submitted a new drug application to the FDA for its once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. The company’s Roclatan product is a fixed-dose combination of two drugs – netarsudil and latanoprost. Aerie’s latest eye drug was proven to be safe and […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Aerie Pharmaceuticals

Aerie launches glaucoma drug in U.S.

April 30, 2018 By Sarah Faulkner

Aerie Pharmaceuticals - updated

Aerie Pharmaceuticals (NSDQ:AERI) today launched its once-daily eye-drop product, Rhopressa, which is designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. The Durham, N.C.-based company won FDA approval for Rhopressa in December last year, two months before the agency was expected to make a decision. “We are pleased to announce the availability in […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals

Glooko names digital health veteran as CEO | Personnel Moves – April 17, 2018

April 17, 2018 By Sarah Faulkner

Glooko

Glooko named health tech veteran Russ Johannesson as its new chief executive this month, adding that the diabetes data management company’s former CEO, Rick Altinger, is slated to become EVP of corporate development. Johannesson previously served as the chief operating officer of Sharecare, a digital health and wellness platform. Before that he led sales, marketing […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, depomed, glooko, Glytec, milestonescientific, natera, Nemaura Medical, Orchard Therapeutics, perkinelmer, pneumarespiratory

Aerie misses Q4 earnings estimates by 11¢

March 1, 2018 By Sarah Faulkner

Aerie Pharmaceuticals - updated

Shares in Aerie Pharmaceuticals (NSDQ:AERI) held steady today after the eye-drug maker missed earnings expectations on Wall Street with its fourth-quarter and full-year financial results. The Durham, N.C.-based company posted a net loss of -$58.5 million, or -$1.60 per share, for the 3 months ended Dec.31. Adjusted to exclude 1-time items, earnings per share were -$1.38, behind […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals

Anthem exec chairman joins Proteus board | Personnel Moves – Feb. 26, 2018

February 26, 2018 By Sarah Faulkner

Proteus Digital Health

Proteus Digital Health announced earlier this month that Anthem‘s (NYSE:ANTM) executive chairman, Joseph Swedish, joined the company’s board of directors. Swedish served as Anthem’s president & chief executive from 2013 until he was appointed executive chairman in 2018. “Proteus has created a compelling solution to a problem that has plagued the pharmaceutical industry for decades: […]

Filed Under: Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, Allergan, Anthem, BioCorRx, Brainstorm Cell Therapeutics, Chrono Therapeutics, infusystem, Proteus Digital Health, Reva Medical, zynosolutions

SureFire Medical names pharma vet Szela as president, CEO | Personnel Moves – Jan. 26, 2018

January 26, 2018 By Sarah Faulkner

Surefire Medical

SureFire Medical has named pharma veteran Mary Szela as its president, CEO and board member, succeeding founder James Chomas, who has served as the company’s chief executive and president since 2009. Chomas will assume the role of chief technology officer and oncology strategy officer, focusing his efforts on the the company’s oncology drug-delivery tech. “Immune […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, cingulatetherapeutics, Eyenovia Inc., Flexion Therapeutics, milestonescientific, Ocular Therapeutix, PolyPid, surefiremedical

Aerie Pharmaceuticals prices $75m public offering

January 24, 2018 By Sarah Faulkner

Aerie

Aerie Pharmaceuticals (NSDQ:AERI) has priced an underwritten public offering of $75 million in shares of its common stock. The Irvine, Calif.-based company also plans to grant underwriters a 30-day option to buy up to $11.3 million in shares of common stock. Aerie reported that it plans to use the net proceeds from the offering to fund […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals

Aerie’s glaucoma eye drops win early FDA nod

December 19, 2017 By Sarah Faulkner

Aerie

Aerie Pharmaceuticals (NSDQ:AERI) won an early FDA nod for its glaucoma drug, Rhopressa. The agency was slated to make a decision about the company’s eye drops in February. The win for Aerie came after an expert panel voted 9-1 in the drug’s favor. Studies have found that Rhopressa lowers elevated intraocular pressure in the eye, but analysts […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Aerie Pharmaceuticals

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS